Lario Therapeutics

Lario Therapeutics is developing first-in-class precision medicines as disease-modifying treatments for severe neurological disorders, including genetically defined epileptic encephalopathies and Parkinson's disease.

The company's pipeline centres on neuronal calcium channel inhibitors, beginning with genetically validated targets linked to early childhood epilepsy syndromes and expanding into adult neurodegenerative conditions.

Lario has received multiple grants from the Michael J. Fox Foundation supporting its calcium channel platform, reflecting growing validation of its precision neuroscience approach.